Neoadjuvant denosumab for the treatment of a sacral osteoblastoma

Eur Spine J. 2018 Jul;27(Suppl 3):446-452. doi: 10.1007/s00586-018-5461-z. Epub 2018 Jan 22.

Abstract

Purpose: To present a case of aggressive sacral osteoblastoma (OB) treated with neoadjuvant denosumab therapy and en bloc resection.

Methods: Case report of a 14-year-old male with an aggressive OB affecting the superior articular process of the left first sacral segment. The lesion was lytic and metabolically active and involved the left-sided posterior elements of S1-S3 with extension into the spinal canal, affecting the left S1, S2, S3, S4 and S5 nerve roots. He was treated for 1 month with neoadjuvant denosumab followed by en bloc resection.

Results: Denosumab therapy caused regression of the tumour and converted the diffuse infiltrative mass into a well-defined solid (osteoma-like) structure, aiding surgical resection and preserving the S1, S4 and S5 nerve roots. Histologically, the treated lesion showed abundant sclerotic woven bone and osteoblasts with absence of osteoclasts.

Conclusions: A short course of denosumab caused tumour regression, ossification and conversion of an aggressive OB into a sclerotic, well-defined lesion thus aiding surgical resection and preservation of neural structures. Neoadjuvant therapy reduced osteoclast numbers but PET showed that the lesion remained FDG avid post-therapy.

Keywords: Denosumab; Osteoblastoma; RANK; Tumour.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / surgery
  • Denosumab / administration & dosage*
  • Humans
  • Male
  • Neoadjuvant Therapy / methods
  • Osteoblastoma / drug therapy*
  • Osteoblastoma / surgery
  • Positron Emission Tomography Computed Tomography
  • Sacrum / pathology
  • Sacrum / surgery
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Denosumab